iRadimed financials
$86.46−0.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.5M | $22.0M | $22.7M | $21.2M | $20.4M | $19.5M | $19.4M | $18.3M | $17.9M | $17.6M | $17.5M | $16.5M |
| Gross profit | $15.2M | $16.8M | $17.0M | $16.5M | $16.0M | $14.8M | $14.8M | $14.2M | $14.0M | $13.4M | $13.4M | $12.8M |
| Gross margin | 74.1% | 76.5% | 75.1% | 77.8% | 78.2% | 76.1% | 76.1% | 77.4% | 78.1% | 76.1% | 76.9% | 77.8% |
| Operating income | $6.4M | $7.2M | $7.1M | $6.8M | $6.8M | $5.4M | $5.8M | $5.8M | $5.6M | $4.7M | $5.2M | $5.9M |
| Net income | $5.2M | $5.8M | $6.4M | $5.6M | $5.8M | $4.7M | $5.1M | $5.0M | $4.9M | $4.1M | $4.5M | $5.1M |
| Net margin | 25.5% | 26.5% | 28.4% | 26.3% | 28.3% | 24.0% | 26.5% | 27.6% | 27.3% | 23.5% | 26.0% | 30.7% |
| Diluted EPS | $0.41 | $0.45 | $0.50 | $0.43 | $0.45 | $0.37 | $0.40 | $0.40 | $0.38 | $0.32 | $0.36 | $0.40 |
| EBITDA | $6.8M | $7.7M | $7.5M | $7.2M | $7.0M | $5.6M | $6.0M | $6.0M | $5.8M | $5.0M | $5.4M | $6.1M |
| Operating cash flow | $5.9M | $8.3M | $5.9M | $7.0M | $7.7M | $4.3M | $6.0M | $9.1M | $6.6M | $3.9M | $3.9M | $1.4M |
| Free cash flow | $5.8M | $7.9M | $5.5M | $5.7M | $5.1M | $595.0K | $2.9M | $5.1M | $5.4M | $3.4M | $3.3M | $953.7K |
| Diluted shares | 12.9M | 12.9M | 12.9M | 12.9M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 12.7M | 12.7M | 12.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $59.1M | $56.4M | $51.2M | $56.5M | $53.0M | $50.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $115.0M | $114.4M | $108.8M | $114.7M | $106.4M | $101.7M |
| Total liabilities | $13.2M | $15.9M | $14.2M | $16.4M | $12.1M | $11.7M |
| Shareholders' equity | $101.7M | $98.5M | $94.6M | $98.4M | $94.3M | $90.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology